Stockreport

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]

Elicio Therapeutics, Inc.  (ELTX) 
PDF • AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T c [Read more]